#China #Shanghai #Frost & Sullivan #Viva Biotech #AI Drug Discovery

Viva Biotech Honored with Frost & Sullivan Award

Viva Biotech, a pioneer in the field of drug discovery, has recently received the esteemed 2025 APAC Technology Innovation Leadership recognition from Frost & Sullivan. This accolade acknowledges the company’s exceptional contributions to the Integrated Intelligent Drug Discovery sector, particularly in enhancing efficiencies in preclinical research and development.

Transforming Drug Discovery With AI

What truly sets Viva Biotech apart is its innovative integration of artificial intelligence (AI) in the drug discovery process. The company has developed platforms that not only accelerate timelines but also reduce costs while pushing the boundaries of therapeutic innovations globally. This recognition from Frost & Sullivan highlights how Viva Biotech has consistently demonstrated leadership by merging cutting-edge technology with laboratory validations to redefine the future of drug development.

The award, presented annually, is a testament to organizations that excel in strategic development and execution. Viva Biotech emerged as a leader in this competitive landscape thanks to its rigorous benchmarking in strategy effectiveness and execution.

Priyanka Jain, a senior research analyst at Frost & Sullivan, elaborated on the company’s impact:

"By integrating multimodal artificial intelligence with extensive wet lab validation, Viva Biotech has established one of the most versatile discovery platforms in the industry. Its ability to support diverse modalities—from small molecules to antibodies and even emerging therapies—has significantly reduced development timelines and costs for clients worldwide."

AI-Driven Drug Discovery Platform

At the core of Viva Biotech’s operations is its AI-Driven Drug Discovery (AIDD) platform, which comprises sophisticated components like V-Scepter, V-Orb, and V-Mantle. These modules provide solutions for long-standing challenges in drug design through a blend of predictive modeling, physics-based simulations, and generative AI. This unique combination enables swift validation and iterative improvements of drug candidates.

• - V-Scepter: Forms the foundation of the platform by automating parameterization for biological systems, including complex small molecules and peptides.
• - V-Orb: Focuses on physics-driven modeling to optimize non-covalent and covalent binders, accelerating drug discovery through active learning and virtual screening.
• - V-Mantle: Harnesses generative AI to support protein structure predictions and antibody engineering workflows, further streamlining the drug discovery process.

Efficiency and Cost-Effectiveness

Viva Biotech's integrated platform allows it to support over 150 projects for more than 50 global clients, achieving discovery cycles that are 30-50% faster. Moreover, the company reports cost savings of up to 70%, consistently maintaining high success rates across various challenging targets. These improvements empower their partners to propel preclinical programs forward efficiently, thus accelerating the provision of cutting-edge therapies.

The company’s agile response to the evolving landscape of pharmaceutical research is commendable. With a focus on integrating AI-driven modeling and structure-based drug discovery, Viva Biotech facilitates swift decision-making for its partners, endorsing first-in-class programs worldwide.

A Vision for the Future

Dr. Derek Ren, CEO of Viva Biotech, expressed gratitude for the recognition, stating,

"We are very honored to receive this award from Frost & Sullivan. This recognition validates our vision of building a genuinely integrated platform that unites AIDD with SBDD. The pace of AI-driven drug discovery is transforming healthcare, and we are excited to continue leading in this new era of scientific innovation."

As Vivo Biotech continues to leverage its AI capabilities to navigate the challenges of drug discovery, the future looks promising for the pharmaceutical industry, heralding a new approach to delivering therapies that were once beyond reach.

For additional details about the recognition, you can read Frost & Sullivan’s full report here.

About Viva Biotech

Founded in 2008, Viva Biotech (01873.HK) offers an extensive range of services from early-stage Structure-Based Drug Research and Development to commercial manufacturing. By fusing advanced technologies with expertise, Viva Biotech addresses the needs of biopharmaceutical innovators globally, enhancing every aspect of therapeutic strategies and drug modalities.